Nektar Therapeutics (NKTR)
Nektar Therapeutics is a San Francisco biopharmaceutical company developing immunotherapy drugs for autoimmune diseases and cancer. It last closed at $35.91 on Nov 17, down 1.45% on the day. NKTR last reported earnings on Thu, Nov 12, 2026. The average 12-month price target from 6 analysts is $104.17 (+190.1% from the last close), with a high of $178.00 and a low of $50.00. Analyst consensus is Buy, based on the latest ratings from 6 firms (3 buy, 3 hold, 0 sell). Over the past 90 days StreetAlpha recorded 2 whale options trades in NKTR, 50% of them bullish and 50% bearish.
Key Stats
Last 12 monthsNot reported for this period.
From NKTR's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 13). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 6 analysts who set a price target on NKTR in the past 90 days. The average target is $104.17, with a high of $178.00 and a low of $50.00, compared with the last close of $35.91.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 16 | Canaccord Genuity | Target lowered | Buy | $153 → $149 |
| Oct 12 | UBS | Initiated | Hold | $53 |
| Oct 12 | Leerink Partners | Initiated | Buy | $130 |
| Sep 25 | BTIG | Reiterated | Buy | $178 |
| Sep 23 | Wedbush | Maintained | Hold | $50 |
Technical Analysis
The stock is 5% below its 20 day and 31% below its 50 day average. It is 81% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 34), near oversold. The nearest support is the swing low (Nov 5) at $35.81, and the nearest resistance the Pivot at $35.93.
| RSI (14) | 34.43 | Weak, oversold below 30 | Neutral |
| MACD | -2.45 | Above its signal line | Bullish |
| Stochastic | 21.0 | Middle of its range | Neutral |
| ADX (14) | 32.9 | Trending down | |
| Williams %R | -88.2 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -194.6 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −4.9% | Change over 10 sessions | Bearish |
| ATR (14) | $1.93 | Typical daily range, 5.4% of price |
| RSI (14) | 29.59 | Oversold below 30 | Oversold |
| MACD | -8.26 | Below its signal line | Bearish |
| Stochastic | 3.0 | Near the bottom of its range | Oversold |
| ADX (14) | 27.7 | Trending down | |
| Williams %R | -98.7 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -98.3 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −48.5% | Change over 10 sessions | Bearish |
| ATR (14) | $6.78 | Typical daily range, 18.9% of price |
What happened before
See how NKTR did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How NKTR has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.
Whale Options Flow
90DNo whale options trades in NKTR in the last 90 days.
NKTR Institutional Ownership
Full report →- ●126 buying vs 112 selling
- ●Held by funds -0.3 pts
- ●Funds holding +0
- ▼Superinvestors: 0 added, 2 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 244 | 244 | 0.0% |
| In funds' top 10 | 10 | 10 | 0.0% |
| Held by funds | 104.8% | 105.1% | −0.3 pts |
| New / increased | 39 / 87 | 72 / 101 | −27.2% |
| Reduced / sold out | 71 / 41 | 41 / 48 | +25.8% |
| Put/call ratio | 0.84 | 0.38 | +119.5% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NKTR is in one of them and how their past NKTR trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered NKTR in an article yet. Here's the latest on the wider market.
NKTR Congress Trades
All congress trades →| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Josh GottheimerD · NJ | Sell | $1K – $15K | Jun 21, 2018 | Oct 2, 2018 | 103 d |
| Josh GottheimerD · NJ | Buy | $1K – $15K | Jun 6, 2018 | Oct 2, 2018 | 118 d |
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company based in San Francisco, California. It researches and develops drugs that act on the immune system, with programs aimed at autoimmune diseases such as atopic dermatitis and at cancer. Its main drug candidate, rezpegaldesleukin, is designed to increase the activity of regulatory T cells to help restore immune balance. The company's drugs are still in development, and they are intended for people living with autoimmune and inflammatory conditions.
- Headquarters
- San Francisco, CA
- Founded
- 1990
- Website
- nektar.com ↗


